Nasdaq Copenhagen

Jabra and Lenovo Expand Collaboration to Deliver First Full Microsoft Teams Rooms System

Retrieved on: 
Tuesday, August 16, 2022
Multimedia, SVP, EMEA, VPRO, Microsoft, General manager, Mark (given name), Certification, View, Nasdaq Copenhagen, DKK, Music, GN, Intel Core, Solution, Video game console, Nightclub, Lenovo, Jabra

CUPERTINO, Calif., Aug. 16, 2022 /PRNewswire/ -- Jabra and Lenovo are expanding their collaboration to offer a seamless, easy to use meeting room system optimized for use with Microsoft Teams Rooms – the Jabra PanaCast 50 Room System. The purpose-built, modular room kit provides companies looking to upgrade their meeting room technology for the hybrid working world with enhanced business productivity and collaboration capabilities. The plug-and-play full room system is a first from Jabra and is certified for and preloaded with Teams Rooms software.

Key Points: 
  • CUPERTINO, Calif., Aug. 16, 2022 /PRNewswire/ -- Jabra and Lenovo are expanding their collaboration to offer a seamless, easy to use meeting room system optimized for use with Microsoft Teams Rooms the Jabra PanaCast 50 Room System.
  • The plug-and-play full room system is a first from Jabra and is certified for and preloaded with Teams Rooms software.
  • The PanaCast 50 offers innovative 180-degree Panoramic-4K video and works seamlessly with Microsoft Teams Rooms' front row layout to make hybrid meetings more inclusive and engaging.
  • Building on the initial offering made available in EMEA last year, this joint-offering will be the latest full Teams Rooms system from Jabra.

Beltone announces launch of two new hearing aids as part of continued dedication to patient care & support to its independent network of owners

Retrieved on: 
Tuesday, August 16, 2022
Miniaturization, Wind, Noise, Multimedia, Ear, Jabra, IOS, ReSound, Hearing, Research, The Legend of Heroes, Ear canal, Google, Apple, IPod, Communication, Human, Patient, CIC, Apple Inc., Education, View, Nasdaq Copenhagen, Achievement, IPad, Awareness, IPad Air, SteelSeries, Hearing loss, GN, Software, Weather, Solution, LinkedIn, IPhone, Speech, Kool-Aid, Dentistry, Wood, Mobile phone, Toy, Newsweek, Beltone, Android

GLENVIEW, Ill., Aug. 16, 2022 /PRNewswire/ -- Beltone, named America's #1 Hearing Care Retailer by Newsweek, debuted two new hearing aids today, Beltone Achieve and Beltone Imagine Custom CIC. These hearing aids were designed and engineered with advanced hearing technology to offer more benefits to users so hearing loss doesn't have to slow them down.

Key Points: 
  • These hearing aids were designed and engineered with advanced hearing technology to offer more benefits to users so hearing loss doesn't have to slow them down.
  • For more than 80 years, Beltone has been one of the nation's most trusted and leading hearing care provider.
  • Our Beltone hearing care professionals receive extensive training and education, so they are always equipped with the latest knowledge to bring you the best care.
  • Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.

GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise

Retrieved on: 
Tuesday, August 16, 2022
Hardware, Other Health, Technology, Audio, Video, Apps, Applications, Other Consumer, General Health, Medical Devices, Seniors, Wearables, Mobile Technology, Other Technology, Telecommunications, Software, Consumer, Health, Mobile, Wireless, Miniaturization, Noise, Multimedia, Ear, Custom, Jabra, Trial of the century, IOS, Technology, ReSound, Hearing, The Legend of Heroes, Human, Google, Apple, IPod, Perception, Life, Communication, CIC, Mark (given name), RIE, Apple Inc., Nasdaq Copenhagen, IPad, IPad Air, GN Store Nord, SteelSeries, Hearing loss, Music, Cleveland Hearing & Speech Center, GN, Software, Solution, IPhone, Speech, Kool-Aid, CEST, Personal protective equipment, Mobile phone, Beltone, Android

GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA a new hearing aid platform that will set a new standard in hearing technology and improve how people interact with the world around them.

Key Points: 
  • GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA a new hearing aid platform that will set a new standard in hearing technology and improve how people interact with the world around them.
  • ReSound OMNIA provides significantly better hearing in noisy environments than any previous ReSound hearing aid.
  • View the full release here: https://www.businesswire.com/news/home/20220816005068/en/
    GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise (Photo: Business Wire)
    Despite advances in hearing aid technology over the last 10 years, hearing speech in noisy environments is still a challenge for people with hearing loss.
  • At GN Hearing, we know that hearing in noise and hearing aid comfort are both critically important to hearing aid users, says GN Hearing CEO, Gitte Aabo.

Notification of managers’ transactions

Retrieved on: 
Friday, August 12, 2022
Wind, Corporate Knights, Twitter, Farm, LinkedIn, Nasdaq Copenhagen, Science, Targets, Biodiversity, Instagram, EUR, Renewable energy, Facebook

The rsted vision is a world that runs entirely on green energy.

Key Points: 
  • The rsted vision is a world that runs entirely on green energy.
  • rsted develops, constructs, and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and bioenergy plants.
  • Moreover, rsted provides energy products to its customers.
  • In 2021, the group's revenue was DKK 77.7 billion (EUR 10.4 billion).

Zealand Pharma Announces Financial Results for the First Half of 2022

Retrieved on: 
Thursday, August 11, 2022
FDA, Q&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellectual property, ADSS, NDA, DK, Obesity, Type 2 diabetes, ADS, Failure, Private Securities Litigation Reform Act, Half-life, Growth, Sale, American depositary receipt, Research, Lists of diseases, SBS, Patient, COVID-19, Boehringer Ingelheim, Education, Financial result, Structured Product Labeling, Program, Nasdaq Copenhagen, Peptide, Short bowel syndrome, Asset purchase agreement, MannKind Corporation, PIN, Congenital hyperinsulinism, Intention, DKK, Nasdaq, Professional corporation, Diabetes, Webcast, AstraZeneca, Advertising, Weight loss, Food, Efficiency, Zealand Pharma, Fine chemical, Pharmaceutical industry, Cryptocurrency, Renewable energy, CHI

Copenhagen, DK and Boston, MA, U.S. August 11, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. August 11, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first half of 2022 and provided a corporate update.
  • Cash, cash equivalents, and marketable securities: DKK 864.4 million / USD 120.7 million as of June 30, 2022 (June 30, 2021: DKK 1,282.9 million / USD 205.0 million).
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Disclosure, ADSS, DK, ADS, Securities Exchange Act of 1934, SEC, American depositary receipt, Security (finance), Compliance, Patient, Boehringer Ingelheim, Company, Therapy, Nasdaq Copenhagen, Intention, Â, DKK, Nasdaq, Private Securities Litigation Reform Act, AstraZeneca, Solution, Efficiency, Fine chemical, USD, Zealand Pharma

The companys ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares.

Key Points: 
  • The companys ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares.
  • Zealand has been listed on the Nasdaq Copenhagen since November 2010 under the ticker ZEAL.CO and trades in DKK.
  • The company subsequently listed its ADSs on the Nasdaq Global Select Market in the U.S. in August 2017 under the ticker ZEAL and trades in USD.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

Retrieved on: 
Monday, August 8, 2022
Antibody, Biomarker, Risk, Mortality, CE, Patient, Quality of life, AKI, Company, Risk assessment, Nasdaq Copenhagen, Disease, Physician, Acute kidney injury, Pharmaceutical industry

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management.

Key Points: 
  • BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management.
  • The NGAL Test is CE marked and registered in a number of countries worldwide.
  • BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA.
  • The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange.

ALK upgrades its full-year financial outlook

Retrieved on: 
Thursday, August 4, 2022
EBITDA, A/S, EU, Nasdaq Copenhagen, Allergy, Asthma, DKK, Immunotherapy, OMX

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that based on a strong sales momentum and the outlook for the remainder of the year, ALK has upgraded its full-year outlook.
  • ALK will publish its Q2 performance in connection with the six-month interim report on 11 August 2022.
  • ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma.
  • Headquartered in Hrsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen.

Ørsted to present results for first half-year 2022 on 11 August

Retrieved on: 
Thursday, August 4, 2022
LinkedIn, Instagram, Biodiversity, Nasdaq Copenhagen, Twitter, Wind, Targets, EUR, Corporate Knights, Science, Farm, Renewable energy, Facebook

The rsted vision is a world that runs entirely on green energy.

Key Points: 
  • The rsted vision is a world that runs entirely on green energy.
  • rsted develops, constructs, and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities, and bioenergy plants.
  • Moreover, rsted provides energy products to its customers.
  • rsted ranks as the worlds most sustainable energy company in Corporate Knights' 2022 index of the Global 100 most sustainable corporations in the world and is recognised on the CDP Climate Change A List as a global leader on climate action.

Nordea Bank Abp: Transaction in Own Shares

Retrieved on: 
Monday, July 18, 2022
London, Regulation, Nasdaq Copenhagen, European Central Bank, Policy, United Kingdom, American depositary receipt, London Stock Exchange, Central bank, RNS, Board, EUR, Financial Conduct Authority, Nasdaq Helsinki, Annual general meeting, Compliance, Treasury, Online gambling, Reinsurance, Lease, Car rental, EU, Safe harbor, Nordea

At any given time, the number of own shares collectively held by Nordea and its subsidiaries may not exceed 10% of all the shares in Nordea.

Key Points: 
  • At any given time, the number of own shares collectively held by Nordea and its subsidiaries may not exceed 10% of all the shares in Nordea.
  • Nordea will not repurchase any shares in the United States or in respect of its American Depositary Receipts.
  • Nordea will repurchase the shares using its unrestricted equity and record the repurchases as a deduction from retained earnings.
  • Prior to commencement of the third buy-back programme Nordea holds 6,073,651 treasury shares for remuneration purposes.